Zealand Pharma initiates second Phase 3 trial with dasiglucagon for the treatment of congenital hyperinsulinism
Zealand Pharma A/S - American Depositary Shares (ZEAL)
Last zealand pharma a/s - american depositary shares earnings: 11/15 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
zealandpharma.com
Company Research
Source: GlobeNewswire
Press Release – No. 21 / 2019 Zealand Pharma initiates second Phase 3 trial with dasiglucagon for the treatment of congenital hyperinsulinism Congenital hyperinsulinism (CHI) is a rare pediatric disease with high unmet medical needs and serious, debilitating lifelong complications This Phase 3 trial will evaluate dasiglucagon as treatment for CHI children ages 7 days to 1 year who are dependent on intravenous glucose infusions Dasiglucagon has been granted a Rare Pediatric Disease designation by the FDA for treatment of CHI in November 2019 Copenhagen, December 4, 2019 – Zealand Pharma A/S ("Zealand") (NASDAQ: ZEAL), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that the second Phase 3 trial to evaluate dasiglucagon as a potential treatment option for children with congenital hyperinsulinism (CHI) has been initiated. This Phase 3 trial will enroll up to 12 CHI children
Show less
Read more
Impact Snapshot
Event Time:
ZEAL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZEAL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZEAL alerts
High impacting Zealand Pharma A/S - American Depositary Shares news events
Weekly update
A roundup of the hottest topics